MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 597882 | Name: Ertugliflozin pidolate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ertugliflozin pidolate belongs to the class of potent and selective inhibitors of the sodium-dependent glucose cotransporters (SGLT), more specifically the type 2 which is responsible for about 90% of the glucose reabsorption from glomerulus.

Chemical Structure

Ertugliflozin pidolate
Ertugliflozin pidolate
CAS#1210344-83-4 (pidolate)

Theoretical Analysis

MedKoo Cat#: 597882

Name: Ertugliflozin pidolate

CAS#: 1210344-83-4 (pidolate)

Chemical Formula: C27H32ClNO10

Exact Mass: 565.1715

Molecular Weight: 566.00

Elemental Analysis: C, 57.30; H, 5.70; Cl, 6.26; N, 2.47; O, 28.27

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
1210344-83-4 (pidolate) 1210344-57-2 (free base)
Synonym
Ertugliflozin pidolate; Ertugliflozin L-pyroglutamic acid; PF-04971729; PF 04971729; PF04971729; PF-04971729-00; Ertugliflozin; Steglatro.
IUPAC/Chemical Name
(S)-5-oxopyrrolidine-2-carboxylic acid compound with (1S,2S,3S,4R,5S)-5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol (1:1)
InChi Key
YHIUPZFKHZTLSH-LXYIGGQGSA-N
InChi Code
SMILES Code
O=C([C@H](CC1)NC1=O)O.OC2[C@](O3)(CO)CO[C@]3(C4=CC=C(Cl)C(CC5=CC=C(C=C5)OCC)=C4)[C@H](O)[C@H]2O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 566.00 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Liu J, Patel S, Cater NB, Wu L, Huyck S, Terra SG, Hickman A, Darekar A, Pong A, Gantz I. Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2019 Dec 3. doi: 10.1111/dom.13931. [Epub ahead of print] PubMed PMID: 31797522. 2: Erratum: Ertugliflozin for type 2 diabetes [Correction]. Aust Prescr. 2019 Jun;42(3):115. doi: 10.18773/austprescr.2019.036. Epub 2019 Apr 26. PubMed PMID: 31363318; PubMed Central PMCID: PMC6594852. 3: Fediuk DJ, Matschke K, Liang Y, Pelletier KB, Wei H, Shi H, Bass A, Hickman A, Terra SG, Zhou S, Krishna R, Sahasrabudhe V. Bioequivalence of Ertugliflozin/Sitagliptin Fixed-Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components. Clin Pharmacol Drug Dev. 2019 Oct;8(7):884-894. doi: 10.1002/cpdd.722. Epub 2019 Jun 20. PubMed PMID: 31219248; PubMed Central PMCID: PMC6851892. 4: Common Drug Review New Combination Product: Ertugliflozin/Metformin Fixed-Dose Combination (Segluromet): Merck Canada Inc. Indication: Type 2 Diabetes Mellitus [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Feb. Available from http://www.ncbi.nlm.nih.gov/books/NBK542579/ PubMed PMID: 31211542. 5: Pharmacoeconomic Review Report: Ertugliflozin (Steglatro): (Merck Canada Inc.): Indication: Type 2 Diabetes Mellitus [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Feb. Available from http://www.ncbi.nlm.nih.gov/books/NBK542500/ PubMed PMID: 31211532. 6: CADTH Canadian Drug Expert Committee Recommendation: Ertugliflozin (Steglatro — Merck Canada Inc.): Indication: Diabetes mellitus, type 2 [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jan 25. No abstract available. Available from http://www.ncbi.nlm.nih.gov/books/NBK542402/ PubMed PMID: 31206291. 7: CADTH Canadian Drug Expert Committee Recommendation: Ertugliflozin/Metformin (Segluromet — Merck Canada Inc.): Indication: Diabetes mellitus, type 2 [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jan 25. No abstract available. Available from http://www.ncbi.nlm.nih.gov/books/NBK542401/ PubMed PMID: 31206287. 8: Clinical Review Report: Ertugliflozin (Steglatro): (Merck Canada Inc.): Indication: Type 2 Diabetes Mellitus [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Feb. Available from http://www.ncbi.nlm.nih.gov/books/NBK542486/ PubMed PMID: 31206284. 9: Dawra VK, Liang Y, Wei H, Pelletier K, Shi H, Hickman A, Bass A, Terra SG, Zhou S, Krishna R, Sahasrabudhe V. Bioequivalence of Ertugliflozin/Metformin Fixed-Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components. Clin Pharmacol Drug Dev. 2019 Jun 17. doi: 10.1002/cpdd.703. [Epub ahead of print] PubMed PMID: 31207178. 10: Han DG, Yun H, Yoon IS. A novel high-performance liquid chromatographic method combined with fluorescence detection for determination of ertugliflozin in rat plasma: Assessment of pharmacokinetic drug interaction potential of ertugliflozin with mefenamic acid and ketoconazole. J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Aug 1;1122-1123:49-57. doi: 10.1016/j.jchromb.2019.05.023. Epub 2019 May 25. PubMed PMID: 31153131. 11: Liu J, Tarasenko L, Terra SG, Huyck S, Wu L, Pong A, Calle RA, Gallo S, Darekar A, Mancuso JP. Efficacy of ertugliflozin in monotherapy or combination therapy in patients with type 2 diabetes: A pooled analysis of placebo-controlled studies. Diab Vasc Dis Res. 2019 Sep;16(5):415-423. doi: 10.1177/1479164119842513. Epub 2019 May 13. PubMed PMID: 31081371. 12: Liu J, Pong A, Gallo S, Darekar A, Terra SG. Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials. Cardiovasc Diabetol. 2019 May 7;18(1):59. doi: 10.1186/s12933-019-0856-7. PubMed PMID: 31064361; PubMed Central PMCID: PMC6503446. 13: Nguyen VK, White JR Jr. Overview of Ertugliflozin. Clin Diabetes. 2019 Apr;37(2):176-178. doi: 10.2337/cd18-0097. PubMed PMID: 31057225; PubMed Central PMCID: PMC6468829. 14: Ertugliflozin for type 2 diabetes. Aust Prescr. 2019 Apr;42(2):70-72. doi: 10.18773/austprescr.2019.018. Epub 2019 Feb 28. Review. Erratum in: Aust Prescr. 2019 Jun;42(3):115. PubMed PMID: 31048942; PubMed Central PMCID: PMC6478963. 15: Wang W, Gan N, Sun Q, Wu D, Gan R, Zhang M, Tang P, Li H. Study on the interaction of ertugliflozin with human serum albumin in vitro by multispectroscopic methods, molecular docking, and molecular dynamics simulation. Spectrochim Acta A Mol Biomol Spectrosc. 2019 Aug 5;219:83-90. doi: 10.1016/j.saa.2019.04.047. Epub 2019 Apr 18. PubMed PMID: 31030051. 16: Sharma R, Razdan K, Kuhad A, Kuhad A. Ertugliflozin for the treatment of type 2 diabetes. Drugs Today (Barc). 2019 Mar;55(3):167-175. doi: 10.1358/dot.2019.55.3.2904972. Review. PubMed PMID: 30938372. 17: Li Y, Mu Y, Shi H, Liang Y, Liu Z, Matschke K, Hickman A, Krishna R, Sahasrabudhe V. Pharmacokinetic Properties of Single and Multiple Doses of Ertugliflozin, a Selective Inhibitor of SGLT2, in Healthy Chinese Subjects. Clin Pharmacol Drug Dev. 2019 Apr 1. doi: 10.1002/cpdd.686. [Epub ahead of print] PubMed PMID: 30934166. 18: Ji L, Liu Y, Miao H, Xie Y, Yang M, Wang W, Mu Y, Yan P, Pan S, Lauring B, Liu S, Huyck S, Qiu Y, Terra SG. Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia. Diabetes Obes Metab. 2019 Jun;21(6):1474-1482. doi: 10.1111/dom.13681. Epub 2019 Apr 5. PubMed PMID: 30830724. 19: Dawra VK, Liang Y, Shi H, Bass A, Hickman A, Terra SG, Zhou S, Cutler D, Sahasrabudhe V. A PK/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects. Int J Clin Pharmacol Ther. 2019 Apr;57(4):207-216. doi: 10.5414/CP203343. PubMed PMID: 30802200; PubMed Central PMCID: PMC6528385. 20: Hollander P, Hill J, Johnson J, Wei Jiang Z, Golm G, Huyck S, Terra SG, Mancuso JP, Engel SS, Lauring B, Liu J. Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin. Curr Med Res Opin. 2019 Aug;35(8):1335-1343. doi: 10.1080/03007995.2019.1583450. Epub 2019 Mar 25. PubMed PMID: 30760125.